Pancreatic Adenocarcinoma, Version 2.2012
Margaret A. Tempero(University of California, San Francisco), Dorothy A. Shead(University of the Witwatersrand), Jorge Obando(Duke University), Nipun B. Merchant(University of Miami), Wen Wee(Roswell Park Comprehensive Cancer Center), Joshua D.I. Ellenhorn(Cedars-Sinai Medical Center), Al B. Benson(Northwestern University), Srinadh Komanduri(Northwestern University), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Eric K. Nakakura(University of California, San Francisco), Sean J. Mulvihill(University of Utah), Brian M. Wolpin(Harvard University), Sarah P. Thayer(University of Nebraska Medical Center), Brian G. Czito(Harvard University), William G. Hawkins(Washington University in St. Louis), Edgar Ben‐Josef(University of Michigan–Ann Arbor), Stephen W. Behrman(Baptist Memorial Health Care), Peter Muscarella(The Ohio State University), J. Pablo Arnoletti(University of Alabama at Birmingham), Anitra Tally(Pancreatic Cancer Action Network), Andrew H. Ko(University of California, San Francisco), Albert C. Koong(The University of Texas MD Anderson Cancer Center), Joseph M. Herman(Northwell Health), Aaron R. Sasson(University of Nebraska Medical Center), Steven J. Cohen(Abington Memorial Hospital), John P. Hoffman(Fox Chase Cancer Center), Deborah A. Freedman-Cass(National Comprehensive Cancer Network), Martha B. Pitman, Samuel H. Whiting(Fred Hutch Cancer Center), Ephraim S. Casper(Cornell University), Mokenge P. Malafa(Moffitt Cancer Center)
Cited by 304
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k